0000000000751686

AUTHOR

Adrián Gadano

showing 2 related works from this author

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine mic…

2006

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C–positive pati…

Graft RejectionMaleTime Factorsmedicine.medical_treatmentTACROLIMUSAzathioprineHepacivirusHEPATITIS-CLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundLiving DonorsLongitudinal StudiesC-2IMMUNOSUPPRESSIONHEPATITIS-C DIABETES-MELLITUS C-2 REPLICATION RECURRENCE SURVIVALGraft SurvivalHepatitis CTreatment Outcomesurgical procedures operativeCreatinineSURVIVALEmulsionsFemaleSteroidsImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyHepatitis C virusRenal functionRANDOMIZED STUDYAge DistributionInternal medicinemedicineDiabetes MellitusHumansHypoglycemic AgentsRECURRENCEMonitoring PhysiologicHepatitisTransplantationCreatinineHepatologybusiness.industryLIVER TRANSPLANTATIONDIABETES-MELLITUSmedicine.diseaseSurvival AnalysisTacrolimusSurgerychemistryREPLICATIONCYCLOSPORINESurgerybusinessFollow-Up Studies
researchProduct

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report

2009

Abstract Hepatitis C virus (HCV) genotypes 4, 5 and 6 represent20% of all HCV cases worldwide. HCV-4 is mainly seen in Egypt, where it represents 90% of all HCV cases. Antischistosomal therapy was the main cause of contamination there, followed by procedures performed by informal providers and traditional healers such as dental care, wound treatment, circumcision, deliveries, excision and scarification. It is also highly prevalent in sub-Saharan Africa and in the Middle East. In Europe, its prevalence has recently increased particularly among intravenous drug users and in immigrants. HCV-5 is mainly found in South Africa, where it represents 40% of all HCV genotypes, but four pockets of HCV…

medicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causechemistry.chemical_compoundPharmacotherapyPegylated interferonInternal medicineEpidemiologyPrevalencemedicineHumansHepatologybusiness.industryTransmission (medicine)Ribavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis CVirologydigestive system diseaseschemistryHCVbusinessViral hepatitismedicine.drugLiver International
researchProduct